Nov 14, 2025 02:36PM Tevogen Bio posts 51% reduction in nine-month operating loss

Nov 5, 2025 03:22PM Tevogen expands COVID-19 T cell therapy to cover 65% of US population

Oct 15, 2025 03:55PM Tevogen addresses patient interest in COVID-19 T cell therapy

Sep 8, 2025 09:28AM Tevogen Bio values TVGN-489 therapy at $9-11 billion

Sep 4, 2025 03:50PM Tevogen Bio estimates pipeline drug value at $250 million for cancer treatment

Sep 3, 2025 04:15PM Tevogen highlights COVID-19 treatment data for immunocompromised patients

Aug 11, 2025 11:59AM Tevogen Bio projects $1 billion launch year revenue for oncology pipeline

Aug 6, 2025 03:59PM Tevogen reports 60% rise in institutional stock ownership

Aug 5, 2025 02:32PM Tevogen.AI expands Microsoft, Databricks ties for cancer model beta

Aug 1, 2025 03:58PM Tevogen CEO outlines AI expansion and funding in stockholder letter

Aug 1, 2025 03:32PM Tevogen Bio to receive $1 million grant for AI drug discovery expansion

Jul 30, 2025 12:45PM Tevogen Bio reports 74% insider ownership of outstanding shares

Jul 28, 2025 11:54AM Tevogen develops AI model to accelerate immunotherapy research

Jul 18, 2025 12:39PM Tevogen receives international patent publication for AI peptide prediction technology

May 30, 2025 11:01AM Tevogen Bio (TVGN) Details Tevogen.AI

May 23, 2025 03:57PM Tevogen Bio (TVGN) expands TVGN 489 target population for patients 65+

Apr 30, 2025 03:52PM CD8 Technology Signs Letter of Intent for Tevogen Bio’s (TVGN) In-House Manufacturing Facility

Apr 29, 2025 01:48PM Tevogen Bio (TVGN) Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

Apr 28, 2025 04:38PM Tevogen Bio (TVGN) Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Apr 9, 2025 02:46PM Tevogen Bio (TVGN) Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States

Apr 7, 2025 04:00PM Tevogen Bio (TVGN) Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission

Mar 25, 2025 01:11PM Tevogen Bio (TVGN) Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Mar 10, 2025 12:42PM Tevogen Bio (TVGN) files patent on T Cell vaccine

Mar 4, 2025 07:02AM D. Boral Capital Starts Tevogen Bio (TVGN) at Buy

Mar 3, 2025 12:54PM Tevogen Bio (TVGN) to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Feb 14, 2025 01:17PM Tevogen Bio (TVGN) Shares 2024 Financing Activity

Feb 14, 2025 11:57AM Tevogen Bio (TVGN) CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity

Feb 7, 2025 02:57PM Tevogen Bio (TVGN) Meets BARDA TechWatch Team, Highlighting ExacTcell Technology’s Potential as a Scalable Medical Countermeasure

Jan 28, 2025 03:50PM Tevogen Bio (TVGN) Enters Agreement to Receive Up to $10M of Non-Dilutive Grant Funding

Nov 8, 2024 03:38PM Tevogen Bio (TVGN) Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Nov 5, 2024 09:28AM Tevogen Bio (TVGN) Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Oct 31, 2024 10:57AM Tevogen Bio (TVGN) Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes

Oct 29, 2024 03:43PM Tevogen Bio (TVGN) Reports Nasdaq Listing Compliance, CEO Reaffirms Commitment in Bridging the Information Gap About the Company

Oct 29, 2024 12:44PM Tevogen Bio (TVGN) Signs LoI With CD8 Technology to Build Up to a $50M R&D and Manufacturing Facility

Oct 21, 2024 04:01PM Tevogen Bio (TVGN) Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Oct 21, 2024 01:57PM Tevogen Bio (TVGN) Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

Oct 17, 2024 09:34AM Tevogen Bio (TVGN) Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Fo

Oct 15, 2024 11:36AM Tevogen Bio (TVGN) Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy

Oct 11, 2024 04:00PM Tevogen Bio (TVGN) to Share $1B+ Revenue Potential of its Pipeline Portfolio

Oct 11, 2024 12:12PM Tevogen Bio (TVGN) Extends Pipeline Prioritizing Oncology and Long COVID

Oct 8, 2024 02:40PM Tevogen Bio (TVGN) Highlights Promising Trial Data

Jul 11, 2024 12:21PM Tevogen Bio (TVGN) Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

Jun 11, 2024 03:31PM Tevogen Bio (TVGN) Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts